RU1826971C - Способ получени производных аденозина или их солей - Google Patents

Способ получени производных аденозина или их солей

Info

Publication number
RU1826971C
RU1826971C SU884613189A SU4613189A RU1826971C RU 1826971 C RU1826971 C RU 1826971C SU 884613189 A SU884613189 A SU 884613189A SU 4613189 A SU4613189 A SU 4613189A RU 1826971 C RU1826971 C RU 1826971C
Authority
RU
Russia
Prior art keywords
synthesis
salts
adenosine derivatives
adenosine
reagent
Prior art date
Application number
SU884613189A
Other languages
English (en)
Russian (ru)
Inventor
Эванс Брайан
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Application granted granted Critical
Publication of RU1826971C publication Critical patent/RU1826971C/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SU884613189A 1987-12-23 1988-12-22 Способ получени производных аденозина или их солей RU1826971C (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878729994A GB8729994D0 (en) 1987-12-23 1987-12-23 Chemical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
SU925010893A Division RU2060996C1 (ru) 1987-12-23 1992-02-24 Производные аденозина

Publications (1)

Publication Number Publication Date
RU1826971C true RU1826971C (ru) 1993-07-07

Family

ID=10628947

Family Applications (2)

Application Number Title Priority Date Filing Date
SU884613189A RU1826971C (ru) 1987-12-23 1988-12-22 Способ получени производных аденозина или их солей
SU925010893A RU2060996C1 (ru) 1987-12-23 1992-02-24 Производные аденозина

Family Applications After (1)

Application Number Title Priority Date Filing Date
SU925010893A RU2060996C1 (ru) 1987-12-23 1992-02-24 Производные аденозина

Country Status (35)

Country Link
US (1) US5032583A (enExample)
EP (1) EP0322242B1 (enExample)
JP (1) JP2736088B2 (enExample)
KR (1) KR890009967A (enExample)
CN (1) CN1024198C (enExample)
AT (1) ATA315488A (enExample)
AU (2) AU612747B2 (enExample)
BE (1) BE1002167A5 (enExample)
CA (1) CA1320195C (enExample)
CH (1) CH677495A5 (enExample)
CZ (1) CZ403991A3 (enExample)
DE (2) DE3856154T2 (enExample)
DK (1) DK170894B1 (enExample)
ES (1) ES2012927A6 (enExample)
FI (1) FI90429C (enExample)
FR (1) FR2629715B1 (enExample)
GB (2) GB8729994D0 (enExample)
GR (1) GR1000307B (enExample)
HU (1) HU203364B (enExample)
IE (1) IE61302B1 (enExample)
IL (1) IL88765A (enExample)
IT (1) IT1224840B (enExample)
LU (1) LU87414A1 (enExample)
MX (1) MX14331A (enExample)
NL (1) NL8803140A (enExample)
NO (1) NO171506C (enExample)
NZ (1) NZ227485A (enExample)
PH (1) PH25932A (enExample)
PL (1) PL158800B1 (enExample)
PT (1) PT89328B (enExample)
RU (2) RU1826971C (enExample)
SE (1) SE8804609L (enExample)
SG (1) SG44701A1 (enExample)
YU (1) YU234188A (enExample)
ZA (1) ZA889593B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
FR2665362B1 (fr) * 1990-08-03 1994-12-09 Cepbepe Substance contenant, comme principe actif, une adenosine substitutee en n6 et son application.
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
ES2095960T3 (es) * 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
DK62692D0 (enExample) * 1992-05-14 1992-05-14 Novo Nordisk As
US5672588A (en) * 1992-05-20 1997-09-30 Novo Nordisk A/S Purine derivatives
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
PL316985A1 (en) * 1994-05-10 1997-03-03 Sandoz Ltd Derivatives of adenosine
GB9421133D0 (en) * 1994-10-20 1994-12-07 Glaxo Group Ltd Medicaments
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
AU2022497A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
HUP0103836A3 (en) 1998-06-02 2003-05-28 Osi Pharmaceuticals Inc Uniond Pyrrolo[2,3d]pyrimidine compositions and their use
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6784165B1 (en) * 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
GB9930083D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB9930077D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
DE60236458D1 (de) 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
WO2004100964A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20050118262A1 (en) * 2003-09-17 2005-06-02 Jack Aurora Controlled release formulation
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
CN101712709A (zh) * 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
AU2010288864A1 (en) * 2009-08-31 2012-04-19 Lonza Ltd Process for the preparation of (1S,4R)-2-oxa-3-azabicyclo[2,2.1]hept-5-enes
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130136C (enExample) * 1966-10-20
NL6717061A (enExample) * 1966-12-21 1968-06-24
DE2052596A1 (de) * 1970-10-27 1972-05-04 Boehringer Mannheim Gmbh, 6800 Mannheim Neuartige Verwendung von N(6)-substituierten Adenosin-Derivaten
NL7203984A (enExample) * 1971-04-10 1972-10-12
BE788958A (fr) * 1971-09-18 1973-03-19 Schering Ag Derives d'adenosine et leur procede de preparation
DE2148838A1 (de) * 1971-09-30 1973-04-05 Boehringer Mannheim Gmbh Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben
DE2157036A1 (de) * 1971-11-17 1973-05-24 Boehringer Mannheim Gmbh Neue heterocyclisch substituierte nebularin-derivate und verfahren zu deren herstellung
DE2244328A1 (de) * 1972-09-09 1974-03-21 Boehringer Mannheim Gmbh Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben
DE2338705A1 (de) * 1973-07-31 1975-02-13 Boehringer Mannheim Gmbh Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben
DE2338963A1 (de) * 1973-08-01 1975-02-13 Boehringer Mannheim Gmbh Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben
DE2426682A1 (de) * 1974-06-01 1975-12-11 Boehringer Mannheim Gmbh Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben
AU579412B2 (en) * 1984-10-26 1988-11-24 Warner-Lambert Company N` - substituted adenosines
ZA857998B (en) * 1984-10-26 1986-05-28 Warner Lambert Co N6-substituted adenosines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Патент GB № 1416423, кл. С 07 D 473/34, А 61 К 31/52, 1975. *

Also Published As

Publication number Publication date
NO171506B (no) 1992-12-14
SE8804609L (sv) 1989-06-24
MX14331A (es) 1993-12-01
HUT48903A (en) 1989-07-28
KR890009967A (ko) 1989-08-05
IT1224840B (it) 1990-10-24
SG44701A1 (en) 1997-12-19
IL88765A (en) 1993-04-04
AU8589491A (en) 1991-12-12
IE61302B1 (en) 1994-10-19
PL158800B1 (en) 1992-10-30
SE8804609D0 (sv) 1988-12-21
NO885719D0 (no) 1988-12-22
US5032583A (en) 1991-07-16
EP0322242A2 (en) 1989-06-28
PT89328B (pt) 1993-08-31
DK713488A (da) 1989-06-24
GB2212498B (en) 1991-07-24
CN1035295A (zh) 1989-09-06
BE1002167A5 (fr) 1990-08-28
JP2736088B2 (ja) 1998-04-02
FI885943L (fi) 1989-06-24
CH677495A5 (enExample) 1991-05-31
CA1320195C (en) 1993-07-13
GB8729994D0 (en) 1988-02-03
GB8829983D0 (en) 1989-02-15
FI90429C (fi) 1994-02-10
PL276697A1 (en) 1990-02-19
GR1000307B (el) 1992-05-12
LU87414A1 (fr) 1989-07-07
HK1009650A1 (en) 1999-06-04
DE3856154T2 (de) 1998-08-27
PH25932A (en) 1991-12-19
ATA315488A (de) 1994-02-15
GB2212498A (en) 1989-07-26
IE883845L (en) 1989-06-23
IT8848714A0 (it) 1988-12-23
NO885719L (no) 1989-06-26
PT89328A (pt) 1989-12-29
EP0322242B1 (en) 1998-04-01
ES2012927A6 (es) 1990-04-16
RU2060996C1 (ru) 1996-05-27
DE3843609A1 (de) 1989-07-06
YU234188A (en) 1990-12-31
JPH01203400A (ja) 1989-08-16
CN1024198C (zh) 1994-04-13
EP0322242A3 (en) 1990-04-18
IL88765A0 (en) 1989-07-31
NO171506C (no) 1993-03-24
HU203364B (en) 1991-07-29
CZ403991A3 (en) 1993-04-14
AU2740188A (en) 1989-06-29
DE3856154D1 (de) 1998-05-07
NZ227485A (en) 1991-06-25
FI90429B (fi) 1993-10-29
DK713488D0 (da) 1988-12-21
FR2629715A1 (fr) 1989-10-13
DK170894B1 (da) 1996-03-04
FR2629715B1 (fr) 1993-09-03
AU612747B2 (en) 1991-07-18
NL8803140A (nl) 1989-07-17
ZA889593B (en) 1989-09-27

Similar Documents

Publication Publication Date Title
ATE127801T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung.
FI93353B (fi) Menetelmä ACAT-inhiboivien kinoliinijohdannaisten valmistamiseksi
NO933376D0 (no) Morfinan-derivater og medisinsk anvendelse derav
ES2082805T3 (es) Derivados de tiazol, procedimientos para su produccion y composiciones farmaceuticas que comprenden los mismos.
BR8704582A (pt) Processo para preparar derivados de piridinacarboxamida
ATE110725T1 (de) Organische salze von physostigminderivaten.
DK255786A (da) Quinazolinderivater eller farmaceutisk acceptable salte eller estere deraf, deres fremstilling og anvendelse som farmaceutika
ES8706673A1 (es) Un procedimiento para la preparacion de derivados de 1,4-dihidro-4-oxonaftiridina y sus sales
ES8600210A1 (es) Un procedimiento para la preparacion de nuevos derivados de arilamida
EP0223385A3 (en) 8-azabicycloû3,2,1¨octane and 9-azabicycloû3,3,1¨nonane derivatives
DE3665711D1 (de) Novel guanidinomethylbenzoic acid derivatives
ATE61574T1 (de) N-((2,6-disubstituierte)-phenyl>-harnstoff und - carbamat-inhibitoren der acyl-coenzym a:cholesterol-acyltransferase.
ES8504723A1 (es) Un metodo para preparar derivados de 4-hidroxi-2-quinolonas.
NZ302072A (en) 1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
PT87578A (pt) Process for the preparation of new alkanesulfonanilide derivatives and of pharmaceutical composition comprising the same
JPS5285174A (en) Novel urea or thiourea derivatives
DK0447116T3 (da) Urinstof-derivater, deres fremstilling samt lægemidler indeholdende sådanne derivater
DE3675778D1 (de) (2-amino-4-aryl-thiazol-5-yl)aethanol, und deren derivate mit diuretischer aktivitaet und verfahren zu deren herstellung.
AU590793B2 (en) Phenoxy pthalide derivatives
DK158467C (da) Fremgangsmaade til fremstilling af cinnamoylanthranilsyrederivater
KR840006992A (ko) 피리딘 유도체
ES2171389T3 (es) Derivados anticonvulsivos de aminoacidos.
PT92147A (pt) Processo para a preparacao de derivados de pirrolidina
GB1367305A (en) Benzodiazocine derivatives
PT85547A (pt) Processo de preparacao de composicao farmaceuticas a base de derivados de 2-mercapto-imidazol e de preparacao destes derivados